Last updated: March 9, 2026
What is NDC 45802-0853?
NDC 45802-0853 corresponds to Lutathera (lutetium Lu 177 dotatate), a radiopharmaceutical approved by the U.S. Food and Drug Administration (FDA) in early 2018 for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (NETs). It is marketed by Advanced Accelerator Applications, a Novartis company.
Market Landscape
Indications and Target Population
- Primary indication: Unresectable or metastatic GEP-NETs expressing somatostatin receptors.
- Patient estimates: Data suggest approximately 30,000–50,000 patients in the U.S. with well-differentiated GEP-NETs, with about 50% expressing somatostatin receptors suitable for Lutathera therapy.
Competitive Environment
- Main competitors:
- Somatostatin analogs (e.g., octreotide, lanreotide)
- Peptide receptor radionuclide therapy (PRRT): Lutathera is the only FDA-approved radiopharmaceutical for this indication.
- Alternative therapies: Chemotherapy and targeted agents like everolimus or sunitinib for non-PRRT options.
Market Trends
- The NET treatment market is expanding due to increased diagnosis rates and the emergence of PRRT.
- Adoption of Lutathera is driven by its demonstrated efficacy (ORR ~15-20%), safety profile, and limited competition.
Current Utilization Rates
- Prescription data indicate gradual uptake.
- In 2022, approximately 4,000–5,000 doses sold in the U.S., with the total patient coverage estimated at 2,500–3,000.
- Penetration varies across treatment centers; specialized oncology hospitals lead in adoption.
Price Point Analysis
Current List Price
- As of late 2022, the list price per dose is roughly $27,000 to $30,000 (U.S. dollars), with slight variations by pharmacy and region.
- In Europe, prices range from €20,000 to €25,000, adjusted for local healthcare economics.
Revenue Projections
| Year |
Estimated Doses Sold |
Revenue (USD millions) |
Assumptions |
| 2023 |
6,000 |
$162 million |
A 20% increase from 2022 due to expanded adoption |
| 2024 |
8,000 |
$220 million |
Market penetration broadens with more centers adopting |
| 2025 |
10,000 |
$270 million |
Continued growth, competitive pressures remain low |
Pricing Dynamics
- Negotiated discounts: Insurers and large hospital systems may negotiate prices reducing list prices by 10–15%.
- Reimbursement policies: Centers seek cost coverage through CMS, private insurers, potentially influencing effective patient access.
Pricing Sensitivity
- Slight reductions in list price could expand access and increase total market volume.
- Market sanctions or reimbursement policy changes could pressure prices downward.
Regulatory and Market Risks
- Regulatory hurdles: Any changes in FDA approvals or new safety concerns could influence utilization.
- Market competition: Emerging radiopharmaceuticals targeting NETs could impact market share.
- Manufacturing capacity: The production of lutetium-177, a key input, has been expanding, supporting supply stability.
Summary of Price Trends
| Year |
Average Price per Dose |
Comments |
| 2022 |
$28,000 |
Stable, with some regional discounts |
| 2023 |
$27,500–$28,500 |
Slight decrease possible due to negotiated discounts |
| 2024 |
$27,000–$29,000 |
Price stabilization with increased volume |
Conclusions
Lutathera's market remains limited by suitable patient numbers but holds steady growth potential due to increasing adoption. Price projections suggest stabilization with room for minor decreases due to hospital negotiations. Revenue growth depends on expanded indication approvals and wider treatment adoption.
Key Takeaways
- The U.S. market for NDC 45802-0853 is forecasted to grow at a compound annual growth rate (CAGR) of roughly 15–20% through 2025.
- Price per dose has plateaued around $27,000–$30,000, with discounts reducing net revenue slightly.
- Market expansion relies on broader acceptance within oncology centers and potential new approvals or indications.
- Supply chain stability of lutetium-177 supports market growth without significant price spikes.
- Competition remains limited but could emerge from novel PRRT agents or alternative therapies.
FAQs
1. How does Lutathera compare to other treatment options for GEP-NETs?
Lutathera offers targeted radiotherapy with demonstrated progression-free survival benefits over earlier therapies, with fewer side effects compared to chemotherapy.
2. What is the primary driver of Lutathera's sales growth?
Increased adoption by oncology centers and broader patient access due to expanded indications and improved awareness.
3. Are there ongoing clinical trials impacting Lutathera’s market?
Yes. Trials exploring other radionuclides and combination therapies could influence future market penetration.
4. How do reimbursement policies affect Lutathera pricing?
Reimbursement settings, especially CMS coverage, impact net prices and patient access, influencing manufacturer pricing and marketing strategies.
5. What are the long-term prospects for Lutathera's market share?
Possibility of expansion into other neuroendocrine tumor types and increasing treatment lines could sustain or grow its market share.
References
[1] FDA. (2018). Lutathera (lutetium Lu 177 dotatate) injection.
[2] MarketWatch. (2022). PRRT market analysis and demand estimates.
[3] IQVIA. (2022). U.S. prescription trends for oncology radiopharmaceuticals.
[4] Novartis. (2022). Lutathera product information and pricing.
[5] CMS. (2022). Reimbursement policies for radiopharmaceuticals.
